ANTX
NASDAQ · Pharmaceuticals
An2 Therapeutics Inc
$4.00
+0.09 (+2.30%)
Open$3.76
Previous Close$3.91
Day High$4.25
Day Low$3.76
52W High$6.91
52W Low$1.00
Volume—
Avg Volume7.49M
Market Cap140.53M
P/E Ratio—
EPS$-1.13
SectorPharmaceuticals
Analyst Ratings
Strong Sell
6 analysts
Price Target
+363.8% upside
Current
$4.00
$4.00
Target
$18.55
$18.55
$11.23
$18.55 avg
$22.80
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 8.24M | 7.98M | 7.65M |
| Net Income | 1.80M | 1.81M | 1.71M |
| Profit Margin | 21.9% | 22.7% | 22.3% |
| EBITDA | 3.67M | 3.33M | 3.32M |
| Free Cash Flow | 1.39M | 970.9K | 896.1K |
| Rev Growth | -4.4% | +17.2% | +22.3% |
| Debt/Equity | 1.44 | 1.37 | 1.29 |
Pharmaceuticals Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| LLY | Eli Lilly and Co. | $916.31 | +1.47% | 46.4 | 957.52B |
| JNJ | Johnson & Johnson | $239.93 | +1.98% | 22.2 | 594.00B |
| MRK | Merck & Co. Inc. | $119.37 | +2.58% | 16.5 | 301.17B |
| PFE | Pfizer Inc. | $27.28 | +1.19% | 19.7 | 153.36B |
| BMY | Bristol-Myers Squibb Co | $58.94 | +2.70% | 16.5 | 116.58B |
| ZTS | Zoetis Inc | $116.71 | +0.67% | 21.5 | 57.37B |